F2-CTS-B2M-KO, Clone 30.10
The cell line is not validated yet.
LVPEIi001-C-2
General
iPSC Line |
|
| hPSCreg name | LVPEIi001-C-2 |
| Cite as: | LVPEIi001-C-2 |
| Alternative name(s) |
F2-CTS-B2M-KO, Clone 30.10
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 25th May 2026 |
| Notes | This is an isogenic, B2M gene edited and knockout iPSC line derived from the healthy control iPSC line, LVPEIi001-C. It was generated using an exon 2 targeting sgRNA and an engineered en1FnCas9 encoded CRISPR construct. It carries compound heterozygous biallelic edits within the exon 2 of human B2M gene. The genomic edit in each of the alleles was confirmed by target-region specific PCR amplification and high throughput NGS analysis. The edits caused frameshift in both the alleles and resulted in the total loss of functional protein expression. The isogenic line was clonally expanded beyond passage 20. This clonal line maintained the expression of major stemness markers (OCT4, SOX2, NANOG, KLF4, SSEA4), demonstrated the ability to differentiate into all three germ layers and exhibited a normal female karyotype. |
| User feedback | |
Provider |
|
| Generator |
L.V. Prasad Eye Institute (LVPEI)
Contact:
L.V. Prasad Eye Institute (LVPEI) |
| Owner | L.V. Prasad Eye Institute (LVPEI) |
| Distributors | |
| Derivation country | India |
External iPSC Databases |
|
| BioSamples | SAMEA122715379 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
Terms and conditions apply for commercial use. The MATERIAL cannot be directly used in clinical trials. Any use of the cellular derivatives of the MATERIAL in academic clinical trials must comply with appropriate regional regulatory guidelines for Stem Cell Research and Pluripotent Stem Cell-Derived Cellular Therapies. The REQUESTOR must inform the ORIGINATOR about the intended use. The Limitted Use Label Licence (LULL) for the CTS™ CytoTune™ Technology apply and require prior information and approval from iPS Academia Japan, Inc. |
| Subclone of | |
iPSC Genetic Modification
| Genetic modifications not related to a disease |
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Asian Indian (35 years old) |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | No inherited or systemic disease pathology reported. |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA14207086 |
Ethics
Also have a look at the ethics information for the parental line
LVPEIi001-C
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Addgene |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | For Academic Research Use Only. Any commercial use of this iPSC-line or its derivatives will requires license from iPS Academia Japan, Inc. |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
LVPEIi001-C.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Clonal expansion of cells by seeding at low density |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| NANOG |
Yes |
|||||
| KLF4 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| hTERT |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.